Protocol Ledger

NCT03829657 · Phase III · TERMINATED

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Interventional Phase III clinical trial protocol NCT03829657 sponsored by Theravance Biopharma in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-02-22 Enrollment: 203 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03829657
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)203 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03829657
Protocol FieldVerified Registry Value
NCT IdentifierNCT03829657
Consolidated Lead SponsorTheravance Biopharma
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment203 participants (ACTUAL)
Registered Start Date2019-02-22
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03829657
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->
Rush University Medical CenterChicago, ILOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI